069620 — Daewoong Pharma Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Market Cap
KR₩2tn
Enterprise Value
KR₩3tn
Revenue
KR₩2tn

Annual balance sheet for Daewoong Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	173,734	140,651	137,685	116,347	172,801
Net Total Accounts Receivable
Net Total Receivables	159,635	179,243	177,954	212,456	215,535
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	520,401	548,968	574,824	612,792	732,358
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	395,866	440,890	521,919	675,666	842,341
Net Goodwill
Net Intangible Assets
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	1,410,687	1,563,341	1,770,311	1,976,977	2,362,799
Accounts Payable
Payable / Accrued
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	460,660	472,831	667,117	629,416	588,823
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Total Other Liabilities
Total Funded Status
Total Liabilities	841,156	955,323	1,003,008	1,182,403	1,356,706
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Treasury Stock
Unrealized Gain / Loss
Other Equity
Total Equity	569,531	608,017	767,303	794,574	1,006,093
Total Liabilities & Shareholders' Equity	1,410,687	1,563,341	1,770,311	1,976,977	2,362,799
Total Common Shares Outstanding